423 related articles for article (PubMed ID: 16019530)
1. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Jabbour E; Peslin N; Arnaud P; Ferme C; Carde P; Vantelon JM; Bocaccio C; Bourhis JH; Koscielny S; Ribrag V
Leuk Lymphoma; 2005 Jun; 46(6):861-7. PubMed ID: 16019530
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Caballero MD; Pérez-Simón JA; Iriondo A; Lahuerta JJ; Sierra J; Marín J; Gandarillas M; Arranz R; Zuazu J; Rubio V; Fernández de Sevilla A; Carreras E; García-Conde J; García-Laraña J; Grande C; Sureda A; Vidal MJ; Rifón J; Pérez-Equiza C; Varela R; Moraleda JM; García Ruíz JC; Albó C; Cabrera R; San Miguel JF; Conde E
Ann Oncol; 2003 Jan; 14(1):140-51. PubMed ID: 12488306
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Monjanel H; Deconinck E; Perrodeau E; Gastinne T; Delwail V; Moreau A; François S; Berthou C; Gyan E; Milpied N;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):935-40. PubMed ID: 21109011
[TBL] [Abstract][Full Text] [Related]
9. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
11. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
12. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Pytlík R; Belada D; Kubáčková K; Vášová I; Kozák T; Pirnos J; Bolomská I; Matuška M; Přibylová J; Campr V; Burešová L; Sýkorová A; Berková A; Klener P; Trněný M;
Leuk Lymphoma; 2015 Jan; 56(1):57-64. PubMed ID: 24628294
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
[TBL] [Abstract][Full Text] [Related]
14. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Villa D; Seshadri T; Puig N; Massey C; Tsang R; Keating A; Crump M; Kuruvilla J
Haematologica; 2012 May; 97(5):751-7. PubMed ID: 22180434
[TBL] [Abstract][Full Text] [Related]
15. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Schmitz N; Pfistner B; Sextro M; Sieber M; Carella AM; Haenel M; Boissevain F; Zschaber R; Müller P; Kirchner H; Lohri A; Decker S; Koch B; Hasenclever D; Goldstone AH; Diehl V; ;
Lancet; 2002 Jun; 359(9323):2065-71. PubMed ID: 12086759
[TBL] [Abstract][Full Text] [Related]
16. Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.
Kriegsmann K; Rieger M; Schwarzbich MA; Sitter S; Kriegsmann M; Bruckner T; Hensel M; Ho AD; Witzens-Harig M; Wuchter P
Eur J Haematol; 2018 Jul; 101(1):12-20. PubMed ID: 29575332
[TBL] [Abstract][Full Text] [Related]
17. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
Bertz H; Zeiser R; Lange W; Fetscher S; Waller CF; Finke J
Ann Oncol; 2004 Sep; 15(9):1419-24. PubMed ID: 15319249
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
20. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Linch DC; Yung L; Smith P; Maclennan K; Jack A; Hancock B; Cunningham D; Hoskin P; Qian W; Holte H; Boesen AM; Grigg A; Browett P; Trneny M
Br J Haematol; 2010 Apr; 149(2):237-43. PubMed ID: 20201949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
